Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 13;108(1):45–71. doi: 10.1097/TP.0000000000004624

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 15. — Various relationships between molecular, histological, and clinical variables and graft survival postbiopsy.^108,114 (A) Survival shown per archetype group in 1679 biopsies. B–D, Relative variable importance in random survival forest analysis in (B) all biopsies (N = 1679), (C) biopsies with molecular TCMR (N=175), and (D) biopsies with molecular pure AMR (N = 321). E–H, Association with survival within MMDx pure molecular AMR samples. Graft survival is shown in relation to: (E) DSA status (DSA-positive versus DSA-negative) and (F) AMR_Prob score (expression above or below the median). For comparison, we show the impact of 2 strong predictors of graft loss: (G) the molecular AKI score (IRRAT score) and (H) the molecular atrophy-fibrosis score (ci > 1_Prob, expression above or below the median). AKI, acute kidney injury; AMR, antibody-mediated rejection; DSA, donor-specific antibody; IRRAT, injury- and rejection-associated transcript; TCMR, T cell–mediated rejection.